In the UK, this is the testing strategy for individuals with phaeochromocytoma (<60 years), bilateral phaeochromocytoma or hyperparathyroidism (<50 years), which includes RET in the multigene NGS panel. The gene discussed is RET; the disease is hyperparathyroidism.